November 26, 2013: BioAegis Therapeutics Engages Debra Barngrover to Oversee Recombinant Manufacturing of Plasma Gelsolin

Company to Manufacture Clinical-Grade Supplies for Forthcoming Clinical Trial in Community-Acquired Pneumonia

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 26, 2013) BioAegis Therapeutics announced that it has engaged Debra Barngrover Ph.D. to oversee the company’s recombinant manufacturing of plasma gelsolin. Dr. Barngrover is a pharmaceutical process development expert with extensive experience in protein development. She provides regulatory advice and prepares and reviews the Chemistry, Manufacturing and Controls (CMC) sections of regulatory filings. Most recently, she was Vice President, Technology Development, at Genzyme Corporation. During her tenure at Genzyme, she led the process development team for a recombinant protein from initial product concept through approval to market launch in more than 40 countries.